Anivive Lifesciences Inc.
Long Beach, CA
- UEI
- HR9KVMTD5467
- CAGE
- 8G6Z6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3777 Worsham Ave #200, Long Beach, CA 90808, USA
- Website
- anivive.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| BAA research area 001 - development of vaccine candidates for biodefense and emerging infectious diseases | National Institute of Allergy and Infectious Diseases | $4,889,710 | |
| Comparability protocol for 22.5 MG tablets (nada # 141-526) - project summary/abstract the protocol is to add an… | FDA Office of Acquisition and Grant Services | $214,100 | |
| A multi-center pivotal field study to confirm the effectiveness and safety of verdinexor for the treatment of lymphoma… | FDA Office of Acquisition and Grant Services | $1,000,000 |
About Anivive Lifesciences Inc.
Anivive Lifesciences Inc. is a self-certified small disadvantaged business and for-profit organization that provides research and development services to the federal government, particularly in the areas of vaccine development and veterinary medicine. Registered in SAM.gov since December 2019, the company has received both federal contract and grant awards. Anivive Lifesciences Inc. appears to specialize in developing innovative solutions for animal health and biodefense, working on projects that span from vaccine candidates for emerging infectious diseases to treatments for canine lymphoma.
In June 2024, Anivive Lifesciences Inc. was awarded a significant federal contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This $33,273,522 cost-plus-fixed-fee definitive contract is focused on the development of vaccine candidates for biodefense and emerging infectious diseases. The contract, which is set to run until June 2026, is part of NIAID's Broad Agency Announcement (BAA) research program. The primary objective is to advance the research and development of promising vaccine candidates capable of providing rapid and durable immunity against multiple emerging pathogens. This contract was not set aside for any specific type of business, indicating that Anivive Lifesciences Inc. competed successfully in an open market procurement.
Anivive Lifesciences Inc. has also received federal grant awards from the Center for Veterinary Medicine, demonstrating its involvement in animal health research. In December 2022, the company was awarded a project grant (R01FD007800) to develop an additional strength of Laverdia tablets, a veterinary medication. This grant, running until November 2023, aims to add a 22.5 mg tablet to the existing portfolio of 2.5 mg, 10 mg, and 50 mg tablets, utilizing approved analytical procedures for assessment and testing. Previously, in June 2020, Anivive Lifesciences Inc. received another project grant (R01FD006919) for a multi-center pivotal field study to confirm the effectiveness and safety of Verdinexor for the treatment of lymphoma in dogs. This grant had a duration of three years, ending in May 2023. These grants highlight Anivive Lifesciences Inc.'s commitment to advancing veterinary medicine and developing innovative treatments for animal health conditions.
Quick answers
What is Anivive Lifesciences Inc.'s UEI?
Anivive Lifesciences Inc.'s Unique Entity ID (UEI) in SAM.gov is HR9KVMTD5467.
What is Anivive Lifesciences Inc.'s CAGE code?
Anivive Lifesciences Inc.'s CAGE code is 8G6Z6.
What is Anivive Lifesciences Inc.'s primary NAICS code?
Anivive Lifesciences Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Anivive Lifesciences Inc. located?
Anivive Lifesciences Inc.'s physical address in SAM.gov is 3777 Worsham Ave #200, Long Beach, CA 90808, USA.
Is Anivive Lifesciences Inc. registered in SAM.gov?
Yes. Anivive Lifesciences Inc.'s SAM.gov registration is active through September 17, 2027.
What is Anivive Lifesciences Inc.'s most recent federal award?
Anivive Lifesciences Inc.'s most recent federal contract award is BAA research area 001 - development of vaccine candidates for biodefense and emerging infectious diseases (75N93024C00009), from National Institute of Allergy and Infectious Diseases, on June 7, 2024.
On GovTribe
See Anivive Lifesciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors